Chappidi MR, Welty C, Choi W, et al. - This study was undertaken to investigate the Cancer of the Bladder Risk Assessment (COBRA) score in The Cancer Genome Atlas (TCGA) bladder cancer cohort and to explore the utility of the COBRA score within each bladder cancer molecular subtype following radical cystectomy (RC) and ascertain whether it can help distinguish candidates for adjuvant therapies and clinical trials. RC pathology reports were reviewed to calculate COBRA scores among the TCGA bladder cancer cohort (n=412). They used Kaplan-Meier survival curves along with univariable and multivariable Cox proportional hazard models to ascertain the clinical utility of the COBRA score to predict overall survival (OS) within the overall cohort and within each molecular subtype (if n>30 within subtype). The results confirm the COBRA score in the TCGA bladder cancer cohort. This implies the COBRA score can be applied in conjunction with molecular subtyping information to help guide clinical decision-making following RC to improve risk stratification and allow for earlier identification of candidates for adjuvant therapies and clinical trials.